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1. Abstract  
 This is a review of the relationship of autoimmune diseases to cancer from two perspectives. The first is to 
examine which autoimmune diseases are often associated with increased risk of the development of a malignancy. The 
second is to review which common cancers confer an increased risk of developing an autoimmune disease. In addition, 
some novel approaches to cancer immunotherapy are discussed. 
 
2. Introduction  
 
 Emerging evidence has implicated certain environmental factors such as infections, and dietary 
proteins in the pathogenesis of many autoimmune diseases and cancer1. This article attempts to correlate the common 
factors, with recent updates from the literature. There are many unresolved observations. For example, autoimmune 
thyroid disease is associated with multiple myeloma [odds ratio = 5.68, 95% confidence interval: 1.69-19.13]2. There is  
also a case report of autoimmune disease occurring in a long-term survivor with metastatic colon carcinoma treated 
with a novel chemo-immunotherapy regimen3
 
. GOLFIG-1 is a new translational anticancer regimen based on the 
combined use of gemcitabine, oxalipatin, levofolinic acid and infusional 5-fluorouracil and subcutaneous 
administration of immunoadjuvant cytokines, granulocyte-macrophage-colony stimulating factor (GM-CSF) and very 
low dose interleukin-2 (IL-2). The patient responded to the GOLFIG regimen but developed discoid lupus 
erythematosus. 
 Primary immunodeficiencies (PIDs) are genetic disorders that predispose to frequent and severe infections, 
autoimmunity and cancer4. The expanded life span of such patients increases the overall risk for developing cancer, 
which is now estimated at 4-25%. The type of malignancy depends on the primary immunodeficiency, the age of the 
patient and possibly viral infection. Non-Hodgkin lymphomas predominate, accounting for 60% of cases. The PIDs 
known to be associated with increased incidence of malignancy are: common variable immunodeficiency, IgA 
deficiency, DNA repair disorders, as severe combined immunodeficiency, Wiskott Aldrich syndrome, Klinefelter’s 
syndrome, Chediak-Higashi syndrome, ataxia telangiectasia syndrome. Acquired immunodeficiency diseases include 
iatrogenic immunosuppression as in organ transplant recipients, acquired immunodeficiency syndrome caused by 
human immunodeficiency virus (HIV), and hypogammaglobulinemia. HTLV-1 is associated with adult T cell 
leukemia-lymphoma (ATLL). HIV produces AIDS and the resultant immune deficiency is associated with high-grade 
B-cell lymphoma. Around 60 years ago, infants were given thymic irradiation. Autoimmune diseases appear later in 
life. The disrupted immune system also predisposes them to cancer. 
There may be many mediators and receptors involved. IL-21 is a type I cytokine5
 
 produced by activated 
CD4(+) T cells, NKT cells, and Th17 cells. It has many functions: regulates immunoglobulin production, promotes B 
cell terminal differentiation into plasma cells, cooperatively expands CD8(+) T cells, promotes Th17 differentiation, 
has inhibitory effects on antigen presentation by dendritic cells, and may be pro-apoptotic for B and NK cells. 
Moreover, IL-21 has potent anti-tumor effects while it is also implicated in the development of autoimmune diseases. 
IL-21 research may potentially be helpful in the treatment of a range of illnesses. 
3. Autoimmune disease associated with increased cancer risk  
 Examples of autoimmune disorders associated with development of lymphomas are rheumatoid arthritis, 
lupus erythematosus, Sjögren’s syndrome, Celiac disease and Hashimoto’s thyroidits. 
 
3.1. Rheumatoid arthritis (RA) 
Large granular lymphocyte proliferation may be present in some patients with RA and may sometimes 
progress to T cell large granular lymphocyte leukemia. In addition, the risk of lymphoma is increased in patients with 
RA, whether treated with methotrexate, or with other immunosuppressive agents or not.  
 
3.2. Systemic lupus erythematosus 
The risk of non-Hodgkin lymphomas appears to be increased four to five fold. In particular, 
angioimmunoblastic T cell lymphoma may occur more often than expected.  
 
3.3. Sjögren’s syndrome 
Keratoconjunctivitis sicca refers to the ocular dryness associated with Sjögren’s syndrome. Both Sjögren’s 
syndrome and keratoconjunctivitis sicca are caused by immune-mediated inflammation directed against the exocrine 
glands of the eye and mouth. The histologic features include extensive lymphocytic infiltration, accompanied by 
glandular and ductal atrophy. This lymphocytic infiltration is organized in germinal center-like structures. Salivary 
glands are typically enlarged. 
 
Sjögren’s syndrome is characterized by polyclonal B cell activation as well as lymphocytic infiltration of the 
exocrine glands. This B cell activation predisposes some patients to the development of lymphoma. Most lymphomas 
arise from a reactive infiltrate called lymphoepithelial sialadenitis or a benign lymphoepithelial lesion. The lifetime risk 
of non-Hodgkin lymphoma is increased 16 to 44 times higher than expected, at approximately 5 percent. 
A variety of clinical features appear to identify patients with Sjögren’s syndrome who are at increased risk 
for lymphoma development: cutaneous vasculitis, peripheral neuropathy, rheumatoid factor positivity, type II 
cryoglobulins. Risk factors identified in other studies include anti-Ro/SSA or anti-La/SSB antibody positivity and 
infiltration of salivary glandular tissue by dendritic cells and macrophages that express the cytokines IL-12 and IL-18. 
 
3.4. Celiac disease (Non-tropical sprue) 
Serologic studies, now used to confirm the diagnosis of celiac disease, include the ELISA for IgA antibodies 
to gliadin and the immunofluorescence test for IgA antibodies to endomysium, a structure in the smooth muscle 
connective tissue. Elevated endomysium IgA antibodies are almost a pathognomonic finding. The target autoantigen 
contained within the endomysium was identified as tissue transglutaminase. IgA-antibodies against endomysium and 
the endomysial autoantigen tissue transglutaminase are both highly sensitive and specific. Widespread use of these 
serologic tests has allowed earlier diagnosis, large scale population screening and thereby an improved understanding 
of its epidemiology. These patients have an increased incidence of gastrointestinal non-Hodgkin lymphomas. 
 
4. Autoimmune phenomenon with cancers – paraneoplastic syndromes   
Neurological diseases are defined as paraneoplastic when they occur in increased frequency in patients with 
cancer and are not related to a direct primary or metastatic effect of tumor, infection, metabolic abnormalities, or 
toxicity of therapy6, 7. Autoantibodies and evidence for cellular autoimmunity directed against neuronal, glial, or 
muscle cell antigens have been identified in a number of paraneoplastic neurological disorders8, 9
4.1. Neurological 
. Over the past four 
decades, different investigators identified and reported these disorders using a variety of names. This review employs 
the nosology used by Posner (ref 7? Above):  Paraneoplastic disorders are rare, but accurate diagnosis is important. For 
patients with an occult malignancy, correct diagnosis may lead to the early diagnosis and treatment of the underlying 
malignancy. Effective treatment of the neurologic disorder may improve neurologic dysfunction and improve quality 
of life. Equally important, proper diagnosis of a paraneoplastic disorder spares the patient an extensive and expensive 
search for alternative causes of the neurologic dysfunction.  
Examples of neurological paraneoplastic syndrome include: subacute sensory neuronopathy and 
encephalomyeloneuritis, limbic encephalitis, autonomic neuropathy, progressive cerebellar degeneration, 
paraneoplastic vision loss, opsoclonus-myoclonus, motor neuron disorders, peripheral neuropathies, neuromuscular 
junction disorders, muscle rigidity, dermatomyositis, polymyositis and movement disorders. Details are available in a 
bigger textbook (Devita). The most commonly encountered neurological paraneoplastic syndromes in the clinic are 
neuromuscular junction disorders, and dermatomyositis, polymyositis and will be discussed in detail as follows. 
 
4.1.1. Neuromuscular Junction Disorders 
4.1.1.1. Lambert-Eaton myasthenic syndrome 
The autoimmune disorder of Lambert-Eaton myasthenic syndrome (LEMS) is associated with small cell lung 
carcinoma in 50-60% of cases. Proximal weakness is a common presenting complaint, but bulbar symptoms are 
uncommon. In most patients, LEMS is not a pure motor syndrome. Paresthesias are frequently reported sensory 
findings. The abnormality of autonomic function has been called “cholinergic dysautonomia”. Patients may report dry 
mouth or erectile dysfunction. Characteristic electrophysiologic abnormalities include augmentation of compound 
motor action potentials with repetitive stimulation. Antibodies directed against protein epitopes in the voltage-gated 
calcium channel of presynaptic neurons are present in most patients with LEMS. Passive transfer of antibody 
reproduces the characteristic electrophysiologic abnormality in animal models of LES. Immunization with a 
component of the P/Q-type calcium channel, synaptotagmin, produces autoantibodies and clinical disease in an animal 
model of LES.  Unlike other paraneoplastic syndrome, most patients with LES benefit from plasmapheresis and 
immunosuppressive therapy. Drugs that increase presynaptic acetylcholine release may also decrease symptoms. 3,4-
diaminopyridine is one such agent with relatively minimal side effects. It has been postulated that patients with 
paraneoplastic neurological syndromes such as LEMS have an improved tumour prognosis compared to other patients 
with the tumour but without such neurological deficits10
4.1.1.2.  Myasthenia Gravis                                                                                                                                
 Typical myasthenia gravis is associated with thymoma in approximately 15% of cases, and autoantibodies 
against contractile proteins of striated muscle are associated with increased probability of underlying thymoma. All 
patients with myasthenia gravis should undergo thoracic imaging studies to identify thymic neoplasms. In patients with 
thymoma, the myasthenia gravis often remit after thymectomy.  In almost all cases, the thymoma is not invasive and 
can be definitively treated by thymectomy. The author had come across a patient with unrecognized myasthenia gravis 
and died from respiratory failure. 
. 
 4.1.2. Dermatomyositis and polymyositis 
These conditions are inflammatory myopathies characterized by the subacute development of proximal 
muscle weakness, with or without pain and muscle tenderness. Both conditions are usually idiopathic. Approximately 
10% are associated with cancer. The myopathy usually precedes the diagnosis of the underlying cancer.  Although 
most patients with dermatomyositis do not have cancer, patients with the disorder are probably at a higher risk for 
cancer. When the characteristic findings are present in men older than 40 years, there is a higher incidence of 
underlying cancer, and early detection should be the goal. Breast cancer is the most commonly associated cancer in 
women, and lung and GI cancer in men. Association with tumors of the pancreas, melanoma, germ cell tumors, 
nasopharyngeal carcinoma, and lymphoma has also been reported.  
In addition to proximal symmetric muscle weakness and skin changes, there is usually an elevation in muscle 
creatinine kinase. Electromyography is consistent with a myopathic process. A muscle biopsy usually shows 
inflammatory infiltrates, necrotic fibres, and atrophic fibres, sometimes in a perifascicular pattern. An immune-
mediated intramuscular angiopathy leads to eventual ischemia and muscle fiber necrosis. IgG, IgM, and complement 
deposits are found in small blood vessels. Cellular inflammatory infiltrates include B cells, macrophages, and CD4+ T 
cells.  
Immunosuppression has not been tested specifically in patients with myositis. It is unclear if antineoplastic 
therapy leads to improvement in the muscle disease in the absence of concomitant immunosuppression. Both 
dermatomyositis and polymyositis syndromes follows an inconsistent course and often independent of the cancer 
outcome. 
 
4.2. Others                                                                                           
 Autoimmune hemolytic anemias are typically associated with B-cell malignancies, including chronic 
lymphocytic leukemia and lymphoma, and arise secondary to immunoregulatory abnormalities in these diseases, rather 
than to a direct secretion of tumor-derived substances11. Hallmarks of this disorder disease are a positive direct 
antiglobulin test (Coombs’) result, elevated reticulocyte count, decreased haptoglobin level, and elevated lactate 
dehydrogenase level. Warm or cold antibody immune hemolytic anemias may be seen particularly in the small 
lymphocytic type. Additional autoimmune phenomena, such as circulating anticoagulants (e.g., acquired von 
Willebrand’s disease) may occur, especially in the small lymphocytic lymphomas.  
Warm antibody hemolytic anemia is most commonly associated with lymphoma, chronic lymphocytic 
leukemia, and mucin-producing adenocarcinoma. Cold agglutinin disease is most common in Waldenström's 
macroglobulinemia and lymphomas12
 
. Autoimmune hemolytic anemia is rarely associated with solid tumors. 
However, an association with ovarian, GI, lung, breast, and renal cell cancers has been reported also[Akard AGAIN]. 
Corticosteroid treatment appears to be less effective in autoimmune hemolytic anemia associated with carcinomas than 
in those that are idiopathic or associated with lymphoid malignancies. The Coombs' test result may revert to negative 
with control of the tumor.  
5. Perspectives - Cancer vaccines         
 Immunotherapy for melanoma has undergone significant change since the first attempts to treat patients with 
high dose IL-2. There are now strategies to boost patient antitumor immunity through vaccination, treatment with 
agents that augment host immunity, and adoptive cell transfer13
 Over the last century, vaccine studies have demonstrated that the human immune system, with appropriate 
help, can limit or prevent infection against otherwise lethal pathogens
. The first two strategies have yielded only limited 
clinical success, but adoptive cell transfer therapy, particularly following a lymphodepleting, preconditioning regimen 
has resulted in objective response rates approaching 50%. 
14
 Balancing antitumor efficacy, autoimmunity, and reconstitution of a functioning immune system remain 
challenging and potentially life-threatening issues. Nonmutated tissue differentiation antigens expressed by tumors are 
attractive targets for cancer immunotherapy, but the consequences of a highly effective antitumor immune response on 
. Encouraged by these results, success in 
animal models and numerous well-documented reports of immune-mediated melanoma regression in humans, 
investigators developed melanoma vaccines. However, despite considerable laboratory evidence for vaccine-induced 
immune responses, clinical responses remain poor. Recent studies have elucidated several mechanisms that hinder or 
prevent the creation of successful vaccines and suggest novel approaches to overcome these barriers. Unraveling the 
mechanisms of autoimmunity, dendritic cell activation, regulatory T cells and Toll-like receptors will generate novel 
vaccines that, when used in conjunction with standard adjuvant therapies, may result in improved clinical outcomes. 
self-tissue have not been fully characterized. The infusion of ex vivo expanded adoptively transferred 
melanoma/melanocyte-specific CD8+ T cells that mediated robust tumor killing also induced autoimmune destruction 
of melanocytes in the eye15
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